ribosomal protein L10 likeGenealiases: RPL10_5_1358 · SPGF63
Q-omics provides the consensus-scored RPL10L profile across patient tissues and cancer cell-line models. RPL10L expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RPL10L is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, RPL10L RNA expression shows 10,395 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, COAD, and TGCT as cancer lineages where RPL10L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL10L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL10L survival associations across molecular data types. RPL10L RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL10L RNA expression–survival associations across cancer types. High RPL10L expression shows unfavorable associations in LIHC and ACC, but favorable associations in SKCM, KIRC, UVM and ESCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for RPL10L RNA expression.
This table summarizes RPL10L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL10L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL10L shows lower tumor expression in COAD and READ and higher tumor expression in KIRC, LIHC and PRAD. The COAD box plot shows higher RPL10L RNA expression in normal versus tumor tissue (log2 FC = −1.756, t-test p < 0.001).
This table shows molecular features associated with RPL10L in patient tissues and cancer cell lines. In patient samples, RPL10L shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL10L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and CNS.
